Stratos Wealth Partners LTD. Cuts Position in Eli Lilly and Company (NYSE:LLY)

Stratos Wealth Partners LTD. lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,382 shares of the company's stock after selling 2,129 shares during the period. Stratos Wealth Partners LTD.'s holdings in Eli Lilly and Company were worth $26,745,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Values First Advisors Inc. lifted its holdings in Eli Lilly and Company by 3.7% during the 1st quarter. Values First Advisors Inc. now owns 481 shares of the company's stock worth $397,000 after buying an additional 17 shares during the period. Stratos Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 503.1% during the 1st quarter. Stratos Wealth Advisors LLC now owns 23,942 shares of the company's stock worth $19,774,000 after buying an additional 19,972 shares during the period. Stratos Investment Management LLC lifted its holdings in Eli Lilly and Company by 18.1% during the 1st quarter. Stratos Investment Management LLC now owns 8,284 shares of the company's stock worth $6,842,000 after buying an additional 1,270 shares during the period. Blackhawk Capital Partners LLC. lifted its holdings in Eli Lilly and Company by 41.7% during the 1st quarter. Blackhawk Capital Partners LLC. now owns 8,516 shares of the company's stock worth $7,033,000 after buying an additional 2,504 shares during the period. Finally, Black Diamond Financial LLC lifted its holdings in Eli Lilly and Company by 35.6% during the 1st quarter. Black Diamond Financial LLC now owns 2,996 shares of the company's stock worth $2,475,000 after buying an additional 786 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Guggenheim lifted their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research report on Friday. UBS Group lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Stock Up 0.3%

LLY traded up $2.69 during midday trading on Friday, reaching $793.34. 2,821,127 shares of the company were exchanged, compared to its average volume of 3,667,032. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company's fifty day moving average price is $767.03 and its 200 day moving average price is $800.01. The company has a market cap of $751.88 billion, a price-to-earnings ratio of 64.55, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.58 earnings per share. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company's payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.